Not Yet Recruiting
King's College London
The primary goal of HD123 is to derive biomarkers that could be further developed to measure the efficacy of novel pharmacological treatments for Huntington’s disease (HD).
What is a biomarker? A biomarker is a measurable indicator of a disease or condition. It can for instance be a level of something in your blood or hormon levels. Biomarkers are often measured and evaluated to examine normal biological processes – like measuring the level of hemoglobin in your blood or your blood pressure. In reference to research on Huntingtons disease, a biomarker can tell us something about disease progression – potentially even before symptoms are visible.
Estimated Study Completion Date: 31 March, 2024
Ages Eligible for Study:
21 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
- Must be capable of giving informed consent
- Must be willing to comply with adequate contraceptive measures
- Must be considered by the Investigator to be in good heath (excluding disease under study)
- Individuals who do not meet inclusion criteria
- Known intracranial comorbidities (i.e. stroke, haemorrhage, space-occupying lesions etc.)
- The presence or history of other neurological or primary psychiatric disorders secondary to HD
- Contraindication to MRI (e.g. presence of metal devices, metal deposited in the body)